A biologics product with a market it had not yet reached.

A biologics company had a product that worked and a region that wanted it. What it did not have was a way in. The GCC is not one market. Each country runs its own registration framework, its own pricing, its own view of what should be made locally. A biologics pathway is longer and harder than a small-molecule one, and the cost of getting the sequence wrong is measured in years, not quarters. The company was facing the decisions that set the size of the prize before a single unit had been sold: how to register, whether to build or import, and which market to open first. Each decision constrained the others, and none of them could be run twice cheaply.

The mandate

We were asked to set the GCC entry strategy as one plan rather than a stack of separate calls. Three questions had to be answered together: the registration pathway across the target markets, the manufacture-or-localise decision against real incentives and real cost, and the commercial entry that turned an approved product into a selling one. The company wanted the number, not the encouragement.

What Avior did

We built the registration pathway market by market, then sequenced it as a single programme so the file that opened one market positioned the next rather than starting from zero. On the manufacturing question, we modelled localisation against the incentives on offer, the GMP standard the product's markets demanded, and the volume that would actually run through a plant, then told the company where the case held and where importing was the better return. We did not manufacture a reason to build. The commercial plan named which market led, why, and how pricing and access there would shape the ones that followed. The regulatory ground contact for the biologics pathway was earned on live filings, not read from a guideline.

Outcome

The company entered the GCC on a sequence built to hold rather than a market-by-market improvisation. The registration programme was ordered so early approvals carried later ones instead of each starting cold. The manufacture-or-import decision was made on modelled economics, so capital went where it earned rather than where the incentive pointed. The commercial entry opened in the market that made the strongest platform for the rest. A product that had a region but no route now had both.